CALCIMEDICA INC

Company Overview

CalciMedica is a clinical-stage biotechnology company developing CRAC channel inhibitors, principally the intravenous candidate Auxora, targeting acute critical illnesses driven by inflammatory and calcium‑mediated cell injury (acute pancreatitis, AKI with acute hypoxemic respiratory failure) and certain investigator‑led and preclinical indications. The company is R&D‑focused with a small La Jolla headquarters (≈14 employees), relies on CROs and contract manufacturers, and maintains a global patent portfolio with method‑of‑use protections into the mid‑2040s. Key near‑term value drivers are clinical milestones (the KOURAGE Phase 2 program with expected readout in early 2026 and regulatory interactions around a pivotal AP trial) and access to additional financing; cash runway is reported into mid‑2026 but insufficient to reach approval without more capital.

Executive Compensation Practices

As a small, milestone‑driven biotech, CalciMedica’s executive pay is likely weighted toward equity‑based, performance‑contingent compensation (options, warrants, RSUs and milestone bonuses) to conserve cash and align management with clinical and financing outcomes. Filings show prior one‑time accelerated equity vesting and severance charges (2023) that materially affected G&A, and warrant/promissory‑note fair‑value accounting has meaningfully impacted reported results—factors the board may consider when sizing future equity grants or cash bonuses. The current loan and milestone‑contingent financing structure could push compensation toward retention awards tied to tranche achievement and may introduce covenant‑driven limits or disclosure requirements for certain payouts.

Insider Trading Considerations

Clinical milestones, enrollment updates and trial readouts are material nonpublic information for CalciMedica; insiders will be subject to blackout periods around these events and should use pre‑arranged trading plans (Rule 10b5‑1) to mitigate legal risk. Recent and expected equity financings (2024 private placement, follow‑on, modest ATM activity and the 2025 loan) create predictable windows when insiders have historically sold or may seek liquidity, so watch Section 16 filings for sales following financings. The small employee base and relatively tight float mean insider trades can move the stock more than at larger firms, and non‑cash fair‑value swings in warrants/promissory notes can create short‑term disclosure‑driven volatility that insiders must manage under SEC reporting and company policy.